Tip os
Log ind

Danish biotech to go it alone

Top picks in English:

A Danish biotech has bought out its US partner for a million dollars and will develop its pipeline – which includes a promising diabetes candidate – alone in the future.


COLOURBOX2598921.jpg
Foto: colourbox
by Leonora Beck
Offentliggjort 14.05.13 kl. 09:40

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

Zealand carries out USD 89m IPO in the US

ledelsen i Zealand Pharma.JPG Top picks in English:

Zealand Pharma has listed on the Nasdaq Global Select Market in addition to its listing in Copenhagen, raising USD 89 in the process. But the move does not mean the biotech company has lost faith in the Danish investor base, says CEO Britt Meelby Jensen.

Genmab accelerates research efforts

Top picks in English:

Genmab will need to identify its next winning ticket in the coming three to four years, and its CEO is fully convinced that the drug is already hiding in the biotech company’s pipeline. The firm is now increasing its R&D budget in a bid to identify the winner.

Here is what Danish drug companies pay their workers

Top picks in English:

The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.

Danish hearing aid giants in global showdown

Top picks in English:

The world’s largest hearing device dealer, Amplifon, expresses concern over the entry into the retail market of manufacturers such as William Demant. GN Resound, on the other hand, receives praise and is expected to form even closer ties to its Italian collaborator.

Darzalex is still the “star of the show” for Genmab

Top picks in English:

Genmab’s Darzalex royalties now cover the company’s operating costs and in addition to that, the cancer drug continues its expansion to new markets. And according to CEO, Jan van de Winkel, Genmab could potentially raise its guidance this year.

Novo among the 100 most valuable companies in the world

Top picks in English:

Novo Nordisk has made it onto the list of the world’s 100 most valuable companies for the first time, but the Danish company is still trailing the biggest players in the pharmaceutical industry.

Forsiden lige nu

MedWatch-indeks: Regnskaber rev i forskellige retninger

Regnskab.jpg Medicinal & Biotek:

De to børsnoterede høreapparatselskaber ender i hver sin ende af MedWatch-indekset i en uge, hvor den igangværende regnskabssæson generelt førte til de største udsving på aktiemarkedet.

Disse selskaber hyrer og fyrer mest

Medicinal & Biotek:

Den samlede arbejdsstyrke i verdens største medicinalselskaber er blevet holdt nogenlunde i ro mellem 2015 og 2016. Men i de enkelte selskaber, herunder de to største aktører i Danmark, er der stor forskel på, om man hyrer eller fyrer.

Coloplast-boss: Hensættelser til søgsmål er passende

Medico & Rehab:

Adm. direktør i Coloplast, Lars Rasmussen, forventer, at selskabet snart har afsluttet de resterende produktansvarssager i USA.

Studie viser stor inkompetence blandt sundhedsvæsnets tolke

Sygdom & Sundhed:

Knap halvdelen af dansk-arabisk tolke i det danske sundhedsvæsen er ikke gode nok sprogligt. Det viser et endnu ikke offentliggjort studie. Danske Regioner erkender problemet

Det vil tage 1-2 år mere at fordoble sårforretningen hos Coloplast

Medico & Rehab:

Det er fortsat målet at fordoble sårplejeforretningen for medicoselskabet Coloplast - tidshorisonten har bare skubbet sig lidt, fortæller direktør for sårplejeforretningen.

Lundbeck-direktører udnytter optioner og tegner aktier til rabatpris

Medicinal & Biotek:

Forskningsdirektøren i medicinalselskabet Lundbeck har tegnet 160.000 aktier i selskabet for samlet 25 mio. kr.

ANNONCE
ANNONCE


ANNONCE